IL246719B - רצפי נוגדנים ספציפיים ל e.coli - Google Patents

רצפי נוגדנים ספציפיים ל e.coli

Info

Publication number
IL246719B
IL246719B IL246719A IL24671916A IL246719B IL 246719 B IL246719 B IL 246719B IL 246719 A IL246719 A IL 246719A IL 24671916 A IL24671916 A IL 24671916A IL 246719 B IL246719 B IL 246719B
Authority
IL
Israel
Prior art keywords
specific antibody
antibody sequences
coli specific
coli
sequences
Prior art date
Application number
IL246719A
Other languages
English (en)
Other versions
IL246719A0 (he
Inventor
Eszter Nagy
Gabor Nagy
Valeria Szijarto
Luis Guachalla
Maximiliano Vasquez
Original Assignee
X4 Pharmaceuticals Austria Gmbh
Eszter Nagy
Gabor Nagy
Valeria Szijarto
Luis Guachalla
Maximiliano Vasquez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X4 Pharmaceuticals Austria Gmbh, Eszter Nagy, Gabor Nagy, Valeria Szijarto, Luis Guachalla, Maximiliano Vasquez filed Critical X4 Pharmaceuticals Austria Gmbh
Publication of IL246719A0 publication Critical patent/IL246719A0/he
Publication of IL246719B publication Critical patent/IL246719B/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Gram-negative bacteria
    • C07K16/1228Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56916Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245Escherichia (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50Lipopolysaccharides; LPS
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
IL246719A 2014-02-06 2016-07-11 רצפי נוגדנים ספציפיים ל e.coli IL246719B (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14154158 2014-02-06
EP14166200 2014-04-28
PCT/EP2014/078709 WO2015117711A1 (en) 2014-02-06 2014-12-19 E. coli specific antibody sequences

Publications (2)

Publication Number Publication Date
IL246719A0 IL246719A0 (he) 2016-08-31
IL246719B true IL246719B (he) 2020-09-30

Family

ID=52692587

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246719A IL246719B (he) 2014-02-06 2016-07-11 רצפי נוגדנים ספציפיים ל e.coli

Country Status (12)

Country Link
US (1) US12103962B2 (he)
EP (1) EP3102599B1 (he)
JP (2) JP6590413B2 (he)
KR (1) KR102301188B1 (he)
CN (2) CN106536551B (he)
AU (2) AU2014381795B2 (he)
BR (1) BR112016018116A2 (he)
CA (1) CA2935532A1 (he)
IL (1) IL246719B (he)
MX (1) MX2016008794A (he)
RU (1) RU2724530C2 (he)
WO (1) WO2015117711A1 (he)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.
JP6276427B2 (ja) 2014-02-24 2018-02-07 グリコヴァキシン アーゲー 新規の多糖及びその使用
US9994638B2 (en) * 2015-05-20 2018-06-12 Immunwork Inc. Peptide core-based multi-arm linkers for treating infectious diseases
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
MA42692A (fr) 2015-08-24 2018-07-04 Glaxosmithkline Ip No 2 Ltd Compositions biopharmaceutiques
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
EA202192392A1 (ru) 2019-03-18 2022-02-09 Янссен Фармасьютикалз, Инк. Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EP3938405A4 (en) * 2019-03-20 2022-12-28 Javelin Oncology, Inc. ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS THEREOF
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
WO2022163845A1 (ja) * 2021-01-31 2022-08-04 株式会社バランス・イースト 検査システム、検査方法、プログラム、およびコンピュータが読み取り可能な記憶媒体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
WO2001012646A1 (en) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies
CA2406229C (en) 2000-04-18 2010-09-07 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003901008A0 (en) * 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
EP1844076A2 (en) * 2005-01-31 2007-10-17 Genentech, Inc. Anti-ephb2 antibodies and methods using same
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ, エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2010125565A2 (en) 2009-04-27 2010-11-04 Hadasit Medical Research Services And Development Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
KR102810907B1 (ko) 2010-07-16 2025-05-21 아디맵 엘엘씨 항체 라이브러리
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2867377B1 (en) * 2012-07-02 2019-08-21 The Translational Genomics Research Institute Primers, assays and methods for detecting an e. coli subtype
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.

Also Published As

Publication number Publication date
BR112016018116A2 (pt) 2018-02-20
CN113388032A (zh) 2021-09-14
AU2020287970A1 (en) 2021-01-21
RU2016135962A3 (he) 2018-08-24
MX2016008794A (es) 2016-10-13
KR20160117467A (ko) 2016-10-10
JP2017511691A (ja) 2017-04-27
US20170145079A1 (en) 2017-05-25
RU2724530C2 (ru) 2020-06-23
CA2935532A1 (en) 2015-08-13
AU2014381795B2 (en) 2020-09-17
JP2019213521A (ja) 2019-12-19
CN106536551B (zh) 2021-04-16
EP3102599B1 (en) 2019-02-27
JP6590413B2 (ja) 2019-10-16
CN106536551A (zh) 2017-03-22
EP3102599A1 (en) 2016-12-14
IL246719A0 (he) 2016-08-31
US12103962B2 (en) 2024-10-01
AU2014381795A1 (en) 2016-07-07
RU2016135962A (ru) 2018-03-13
WO2015117711A1 (en) 2015-08-13
KR102301188B1 (ko) 2021-09-13

Similar Documents

Publication Publication Date Title
IL252004A0 (he) נוגדן מוחלף-אתר
SG11201607030PA (en) Antibodies, uses & methods
GB201410825D0 (en) Anti-axl antibodies
GB201410826D0 (en) Anti-axl antibodies
IL246719B (he) רצפי נוגדנים ספציפיים ל e.coli
GB201410520D0 (en) Antibody
IL246603A0 (he) נוגדן חדש נגד נטרין–1
IL248220A0 (he) נוגדן אנטי– nme
GB201511969D0 (en) Biosensor
IL247988A0 (he) נוגדנים נגד hpa–1a
SG11201700922YA (en) Anti-orai1 antibody
PL3112463T3 (pl) Nowe przeciwciało przeciwko presepsynie
GB201416001D0 (en) Pumping mechanism
GB201418661D0 (en) Pumping Mechanism
GB201518806D0 (en) L.e.n.r.
HUP1400305A2 (en) Tideke ......
GB201417023D0 (en) Bizyfy.com
GB201521485D0 (en) .
GB201611093D0 (en) .
GB201400885D0 (en) MagneticChess.com
GB201503899D0 (en) Playat.me
GB201517275D0 (en) Biosensor
GB201503680D0 (en) Whatyouwearing.com
GB201420970D0 (en) eGURE, egure, Egure
GB201403059D0 (en) The S.E.G

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed